FDA Publishes Guidance on Classification of Co-Crystals

News
Article

The agency provides information on the appropriate regulatory classification of pharmaceutical co-crystal solid-state forms.

On Feb. 14, 2018, FDA published guidance for sponsors submitting new drug applications (NDAs) and abbreviated new drug applications (ANDA) regarding the regulatory classification of co-crystal solid-state forms not previously evaluated by the agency and determined to be pharmaceutical co-crystals. The guidance also discusses which data sponsors should submit to support the classification.

According to the guidance, NDA and ANDA applicants should provide evidence to demonstrate that the API and coformers are present in the unit cell, that the component API and coformer co-exist in the co-crystal which interact nonionically, and that substantial dissociation of the API from its co-crystal form occurs before reaching the site of pharmacological activity. “The type and extent of characterization and release testing performed on the co-crystal should be sufficient to ensure the identity, strength, quality, and purity of the API(s),” the document states.

Source: FDA

Recent Videos
Tore Bergsteiner from MAIN5 discusses the most pertinent and impactful bio/pharma industry trends from 2024.
Simon Wright from Almac Pharma Services chats about shifting demand for commercial manufacturing services and how service providers are adapting to meet demand.
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.